



previously filed in this matter did not comply with 37 C.F.R. §§ 1.821-1825. Applicants file herewith a substitute Sequence Listing that is believed to comply with the rules cited above, and a statement regarding content of paper and computer readable copies of the Sequence Listing pursuant to 37 C.F.R. § 1.821. As a result of the filing of the substitute Sequence Listing, Applicants have amended the instant Specification so that it corresponds with the substitute Sequence Listing. Consequently, these amendments introduce no new matter to the instant Application.

**RECEIVED**

JUN 11 2001

*Fees*

TECH CENTER 1600/2900

No fees are believed to be necessitated by the instant response. However, should this be in error, authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments.

**CONCLUSION**

Applicants respectfully request entry of the foregoing amendments and remarks in the file history of the instant Application. Early and favorable action on the Claims is earnestly solicited.

Respectfully submitted,

William C. Coppola  
Attorney for Applicant(s)  
Registration No. 41,686

AVENTIS PHARMACEUTICALS PRODUCTS, INC.  
Route 202-206; Mail Stop: EMC-G1  
P.O. Box 6800  
Bridgewater, NJ 08807  
June 1, 2000